Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Talazoparib plus enzalutamide improves radiographic progression-free survival in HRR-altered mCSPC

Dr Neeraj Agarwal - University of Utah, Salt Lake City, USA
Talazoparib plus enzalutamide improves radiographic progression-free survival in HRR-altered mCSPC ( Dr Neeraj Agarwal - University of Utah, Salt Lake City, USA )
9 Jun 2026

Sacituzumab govitecan improves PFS across Trop-2, BRCA, and HER2 metastatic triple-negative breast cancer

Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA
Sacituzumab govitecan improves PFS across Trop-2, BRCA, and HER2 metastatic triple-negative breast cancer ( Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA )
9 Jun 2026

Sacituzumab govitecan plus pembrolizumab improves PFS across biomarker subgroups in metastatic triple-negative breast cancer

Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA
Sacituzumab govitecan plus pembrolizumab improves PFS across biomarker subgroups in metastatic triple-negative breast cancer ( Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA )
9 Jun 2026

1: Safe administration and dosing of EGFR inhibitors in NSCLC - Practical guidance for oncology nurses

Helena Ullgren, Rachel Powell, Irati Rodriguez-Matesanz and Elin Backman Stålnacke
1: Safe administration and dosing of EGFR inhibitors in NSCLC - Practical guidance for oncology nurses ( Helena Ullgren, Rachel Powell, Irati Rodriguez-Matesanz and Elin Backman Stålnacke )
8 Jun 2026

ASCO 2026: Lung cancer roundup

Dr Luis Raez - Memorial Cancer Institute, Miami, USA
ASCO 2026: Lung cancer roundup ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )
3 Jun 2026

Gedatolisib combinations double PFS vs alpelisib in PIK3CA-mutant advanced breast cancer

Dr Sara Hurvitz - Fred Hutchinson Cancer Center, Seattle, USA
Gedatolisib combinations double PFS vs alpelisib in PIK3CA-mutant advanced breast cancer ( Dr Sara Hurvitz - Fred Hutchinson Cancer Center, Seattle, USA )
2 Jun 2026

ASCO 2026: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada
ASCO 2026: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )
1 Jun 2026

Velzatinib demonstrates broad activity across KIT mutations in advanced gastrointestinal stromal tumours

Dr Neeta Somaiah - The University of Texas MD Anderson Cancer Center, Houston, USA
Velzatinib demonstrates broad activity across KIT mutations in advanced gastrointestinal stromal tumours ( Dr Neeta Somaiah - The University of Texas MD Anderson Cancer Center, Houston, USA )
1 Jun 2026

Optimal panitumumab–bevacizumab sequencing evaluated in RAS wild-type metastatic colorectal cancer

Dr Ramón Salazar - The University of Barcelona, Barcelona, Spain
Optimal panitumumab–bevacizumab sequencing evaluated in RAS wild-type metastatic colorectal cancer ( Dr Ramón Salazar - The University of Barcelona, Barcelona, Spain )
1 Jun 2026

Relacorilant chemo combination extends OS in platinum-resistant ovarian cancer

Dr Lucy Gilbert - McGill University Health Centre, Montreal, Canada
Relacorilant chemo combination extends OS in platinum-resistant ovarian cancer ( Dr Lucy Gilbert - McGill University Health Centre, Montreal, Canada )
1 Jun 2026

Aspirin in stage III colorectal cancer shows no significant DFS benefit but favourable safety

Dr Atsuo Takashima - National Cancer Center Hospital, Tokyo, Japan
Aspirin in stage III colorectal cancer shows no significant DFS benefit but favourable safety ( Dr Atsuo Takashima - National Cancer Center Hospital, Tokyo, Japan )
1 Jun 2026

ASCO 2026: Latest in prostate cancer

Prof Eleni Efstathiou, Prof Boris Hadaschik, Dr Mary-Ellen Taplin and Prof Axel Merseburger
ASCO 2026: Latest in prostate cancer ( Prof Eleni Efstathiou, Prof Boris Hadaschik, Dr Mary-Ellen Taplin and Prof Axel Merseburger )
1 Jun 2026